Disease-modifying  ||| S:0 E:18 ||| JJ
anti-rheumatic  ||| S:18 E:33 ||| JJ
drugs  ||| S:33 E:39 ||| NNS
in  ||| S:39 E:42 ||| IN
rheumatoid  ||| S:42 E:53 ||| JJ
arthritis  ||| S:53 E:63 ||| NN
and  ||| S:63 E:67 ||| CC
ankylosing  ||| S:67 E:78 ||| FW
spondylitis  ||| S:78 E:90 ||| FW
Disease  ||| S:90 E:98 ||| FW
modifying  ||| S:98 E:108 ||| FW
antirheumatic  ||| S:108 E:122 ||| FW
drugs  ||| S:122 E:128 ||| FW
( ||| S:128 E:129 ||| -LRB-
DMARDs ||| S:129 E:135 ||| NNP
)  ||| S:135 E:137 ||| -RRB-
are  ||| S:137 E:141 ||| VBP
widely  ||| S:141 E:148 ||| RB
used  ||| S:148 E:153 ||| VBN
and  ||| S:153 E:157 ||| CC
well  ||| S:157 E:162 ||| RB
accepted  ||| S:162 E:171 ||| VBN
for  ||| S:171 E:175 ||| IN
the  ||| S:175 E:179 ||| DT
treatment  ||| S:179 E:189 ||| NN
of  ||| S:189 E:192 ||| IN
patients  ||| S:192 E:201 ||| NNS
with  ||| S:201 E:206 ||| IN
rheumatoid  ||| S:206 E:217 ||| JJ
arthritis  ||| S:217 E:227 ||| NN
( ||| S:227 E:228 ||| -LRB-
RA ||| S:228 E:230 ||| NNP
) ||| S:230 E:231 ||| -RRB-
.  ||| S:231 E:233 ||| .
Many  ||| S:233 E:238 ||| JJ
studies  ||| S:238 E:246 ||| NNS
have  ||| S:246 E:251 ||| VBP
been  ||| S:251 E:256 ||| VBN
performed  ||| S:256 E:266 ||| VBN
with  ||| S:266 E:271 ||| IN
monotherapy  ||| S:271 E:283 ||| NN
and  ||| S:283 E:287 ||| CC
combinations  ||| S:287 E:300 ||| NNS
of  ||| S:300 E:303 ||| IN
DMARDs  ||| S:303 E:310 ||| JJ
showing  ||| S:310 E:318 ||| VBG
their  ||| S:318 E:324 ||| PRP$
efficacy  ||| S:324 E:333 ||| NN
and  ||| S:333 E:337 ||| CC
safety ||| S:337 E:343 ||| NN
.  ||| S:343 E:345 ||| .
In  ||| S:345 E:348 ||| IN
ankylosing  ||| S:348 E:359 ||| JJ
spondylitis  ||| S:359 E:371 ||| NNS
( ||| S:371 E:372 ||| -LRB-
AS ||| S:372 E:374 ||| NNP
)  ||| S:374 E:376 ||| -RRB-
DMARDs ||| S:376 E:382 ||| NNP
,  ||| S:382 E:384 ||| ,
sulfasalazine  ||| S:384 E:398 ||| VBD
especially ||| S:398 E:408 ||| RB
,  ||| S:408 E:410 ||| ,
are  ||| S:410 E:414 ||| VBP
recommended  ||| S:414 E:426 ||| VBN
only  ||| S:426 E:431 ||| RB
for  ||| S:431 E:435 ||| IN
the  ||| S:435 E:439 ||| DT
peripheral  ||| S:439 E:450 ||| JJ
involvement  ||| S:450 E:462 ||| NN
and  ||| S:462 E:466 ||| CC
not  ||| S:466 E:470 ||| RB
for  ||| S:470 E:474 ||| IN
the  ||| S:474 E:478 ||| DT
axial  ||| S:478 E:484 ||| JJ
symptoms ||| S:484 E:492 ||| NNS
.  ||| S:492 E:494 ||| .
For  ||| S:494 E:498 ||| IN
this  ||| S:498 E:503 ||| DT
disease  ||| S:503 E:511 ||| NN
there  ||| S:511 E:517 ||| EX
is  ||| S:517 E:520 ||| VBZ
a  ||| S:520 E:522 ||| DT
lack  ||| S:522 E:527 ||| NN
of  ||| S:527 E:530 ||| IN
clinical  ||| S:530 E:539 ||| JJ
trials  ||| S:539 E:546 ||| NNS
and  ||| S:546 E:550 ||| CC
most  ||| S:550 E:555 ||| JJS
of  ||| S:555 E:558 ||| IN
the  ||| S:558 E:562 ||| DT
trials  ||| S:562 E:569 ||| NNS
did  ||| S:569 E:573 ||| VBD
not  ||| S:573 E:577 ||| RB
show  ||| S:577 E:582 ||| VB
efficacy  ||| S:582 E:591 ||| VBN
on  ||| S:591 E:594 ||| IN
the  ||| S:594 E:598 ||| DT
axial  ||| S:598 E:604 ||| JJ
symptoms  ||| S:604 E:613 ||| NNS
of  ||| S:613 E:616 ||| IN
the  ||| S:616 E:620 ||| DT
disease ||| S:620 E:627 ||| NN
.  ||| S:627 E:629 ||| .
In  ||| S:629 E:632 ||| IN
this  ||| S:632 E:637 ||| DT
paper ||| S:637 E:642 ||| NN
,  ||| S:642 E:644 ||| ,
the  ||| S:644 E:648 ||| DT
differences  ||| S:648 E:660 ||| NNS
and  ||| S:660 E:664 ||| CC
similarities  ||| S:664 E:677 ||| NNS
of  ||| S:677 E:680 ||| IN
DMARDs  ||| S:680 E:687 ||| JJ
in  ||| S:687 E:690 ||| IN
the  ||| S:690 E:694 ||| DT
treatment  ||| S:694 E:704 ||| NN
of  ||| S:704 E:707 ||| IN
RA  ||| S:707 E:710 ||| NNP
and  ||| S:710 E:714 ||| CC
AS  ||| S:714 E:717 ||| NNP
patients  ||| S:717 E:726 ||| NNS
will  ||| S:726 E:731 ||| MD
be  ||| S:731 E:734 ||| VB
discussed ||| S:734 E:743 ||| VBN
.  ||| S:743 E:745 ||| .
